Efavirenz 600 MG Oral Tablet — RxCUI 349477
RxNorm drug concept · Semantic clinical drug
RxCUI 349477
Semantic clinical drug · SCD
● Current RxNorm concept 5 FDA products
8 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI349477
Official nameEfavirenz 600 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped5
Package NDCs mapped8
Reported Medicaid activity (SDUD)694 prescriptions · 8 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Efavirenz: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- Efavirenz is an antiretroviral medicine — it treats HIV-1 infection. It works by blocking an enzyme the virus needs to make copies of itself. It won't cure HIV, but used consistent...
- What exactly is efavirenz and what is it treating in my body?
- That's actually one of the most common things people notice with efavirenz, and it can feel unsettling. Dizziness, vivid or strange dreams, trouble sleeping, and foggy thinking are...
- Why do I feel so dizzy and have such weird dreams since starting this medication?
🕸️ Concept Web — How Efavirenz 600 MG Oral Tablet Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Efavirenz 600 MG Oral Tablet
RxCUI 349477 Semantic clinical drug · SCD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Efavirenz
195085IN
-
Efavirenz
-
Dose forms 6
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Efavirenz Oral Tablet
378299SCDF -
Efavirenz Oral Product
1161289SCDG -
Efavirenz Pill
1161290SCDG -
Oral Tablet
317541DF -
Oral Product
1151131DFG -
Pill
1151133DFG
-
Efavirenz Oral Tablet
-
Clinical & branded drugs 1
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Efavirenz 600 MG
350652SCDC
-
Efavirenz 600 MG
Showing up to 8 concepts per family — 8 of 8 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Efavirenz 600 MG
SCDC · 350652 -
Efavirenz Oral Tablet
SCDF · 378299 -
Efavirenz Oral Product
SCDG · 1161289 -
Efavirenz Pill
SCDG · 1161290
📦 FDA Products & Package NDCs
5 products · 8 package NDCs
8 package NDCs map to RxCUI 349477 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 31722-0504-25 | 250 TABLET, FILM COATED in 1 BOTTLE (31722-504-25) | Efavirenz | Camber Pharmaceuticals, Inc. | 2018-04-27 |
| 31722-0504-30 | 30 TABLET, FILM COATED in 1 BOTTLE (31722-504-30) | Efavirenz | Camber Pharmaceuticals, Inc. | 2018-04-27 |
| 33342-0013-07 | 30 TABLET in 1 BOTTLE (33342-013-07) | Efavirenz | Macleods Pharmaceuticals Limited | 2024-05-10 |
| 65862-0049-10 | 3 BLISTER PACK in 1 CARTON (65862-049-10) / 10 TABLET, FILM... | Efavirenz | Aurobindo Pharma Limited | 2018-09-21 |
| 65862-0049-30 | 30 TABLET, FILM COATED in 1 BOTTLE (65862-049-30) | Efavirenz | Aurobindo Pharma Limited | 2018-09-21 |
| 69097-0301-02 | 30 TABLET, FILM COATED in 1 BOTTLE (69097-301-02) | Efavirenz | Cipla USA Inc. | 2018-06-18 |
| 72865-0172-25 | 250 TABLET, FILM COATED in 1 BOTTLE (72865-172-25) | EFAVIRENZ | XLCare Pharmaceuticals Inc. | 2021-05-29 |
| 72865-0172-30 | 30 TABLET, FILM COATED in 1 BOTTLE (72865-172-30) | EFAVIRENZ | XLCare Pharmaceuticals Inc. | 2021-05-29 |
Observed labelers:
Aurobindo Pharma Limited (2) ·
Camber Pharmaceuticals, Inc. (2) ·
XLCare Pharmaceuticals Inc. (2) ·
Cipla USA Inc. (1) ·
Macleods Pharmaceuticals Limited (1)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.